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A B S T R A C T
Although LVT is currently extensively prescribed in childhood epilepsy, its effect on the panel of
refractory epilepsy syndromes has not been entirely evaluated prospectively. In order to study the
efﬁcacy and safety of LVT as adjunctive therapy according to syndromes, we included 102 patients with
refractory seizures (6 months to 15 years) in a prospective open-labeled trial. The responder rate was
respectively 36% and 32% at 3 and 6 months with 6% and 7% patients becoming seizure free. Among the
responders at 6 months (n = 33), seizure frequency decreased by 66% and 79% at 3 and 6 months LVT
compared to baseline. The highest beneﬁt was for CSWS patients with 2/3 responders, 50% seizure free
and no aggravation. LVT provided respectively 39% and 42% responders in focal and absence epilepsies.
Infantile spasms and Dravet syndrome experienced the lowest efﬁcacy. No patient with myoclonic-
astatic epilepsy or Lennox–Gastaut syndromewas aggravated. LVT dose over 40 mg/kg/d was associated
with a lower response rate. Tolerability was excellent. In spite of a small sample, we assume that CSWS is
a good candidate for a randomized-controlled trial with LVT.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Among the new antiepileptic drugs evaluated in children over
the past 20 years, levetiracetam (LVT) is quite remarkable for
many reasons. After the US Food and Drug Administration and
the European Medicines Agency approval as adjunctive therapy
for epilepsy with refractory partial onset seizures (POS) in
children aged 4–16 years,1 it was also the ﬁrst to be approved in
infants aged 1 month to 4 years.2 LVT has a large spectrum of
action and its effect was also shown to expand to adolescent
idiopathic generalized epilepsy (IGE), namely juvenile myoclonic* Corresponding author at: U663, Service de Neurologie et Metabolisme, Hopital
Necker, 149 rue de Sevres, 75015 Paris, France. Tel.: +33 1 42192700;
fax: +33 1 42192874.
E-mail address: catherine.chiron@nck.aphp.fr (C. Chiron).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.12.017epilepsy, juvenile absence epilepsy and generalized tonic–clonic
seizures of awakening.3–5 LVT can be co-administered with any
drug since it is not metabolized by the hepatic cytochrome P450
system.6 Because of its favorable safety proﬁle and lack of impact
on child cognition,7 LVT monotherapy studies are emerging in
idiopathic epilepsies: LVT proved to be as efﬁcient as oxcarba-
zepine in BECTS (benign epilepsy with centro-temporal spikes)8
and preliminary open prospective data suggested that it might be
useful as ﬁrst line in Jeavons syndrome (eyelid myoclonia with
absences), Panayiotopoulos syndrome, and occipital epilepsy of
Gastaut type.9–13
Besides these two major groups of pediatric epilepsy patients,
refractory Epilepsy with POS and idiopathic generalized/partial
epilepsy, epileptic encephalopathy represent a third group, highly
refractory and speciﬁc to pediatrics.14 However, in none of them is
there any controlled trial performed with LVT. Although open-
labeled prospective studies are still scarce, they suggest that LVTvier Ltd. All rights reserved.
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athy and that Dravet syndrome may be a target.16 Among the
many retrospective data drawn from large series of children with
pharmaco-resistant epilepsy,17–21 several studies identiﬁed the
epileptic encephalopathy with CSWS (continuous spikes and
waves during sleep) as a potential candidate for LVT therapy.22–27
However, this syndromehas not been prospectively studied so far.
To further evaluate the efﬁcacy of LVT in the entire panel of
pediatric epilepsy syndromes, we performed a prospective open-
labeled study of LVT as adjunctive therapy in a large and non-
selected population of children aged from 6 months to 15 years
with refractory seizures.
2. Materials and methods
2.1. Study design
Patients were recruited from ﬁve French centers for pediatric
third-line epilepsy care. The study was approved by the Paris-
Cochin ethics committee and was carried out in accordance with
the Declaration of Helsinki and guidelines for Good Clinical
Practice. The study was designed and built directly by the
clinicians, and it was sponsored by FFRE (French Foundation for
Research in Epilepsy). The trial was not included in the plan of
development of UCB Pharma which nevertheless partially funded
it. Inclusion criteria were the following: (1) age between 6 months
and 15 years, (2) from one to a maximum of three AEDs at a stable
dosage for at least one month, (3) countable seizures, (4)
pharmaco-resistant epilepsy with the persistence of at least 8
seizure a month, at a stable frequency for 1 month before the
inclusion, and (5) written consent from parents or legal guardian,
who had to be able to record seizures in a diary. The type of
epilepsy was determined based on seizure types as partial or
generalized and based on epilepsy syndrome classiﬁcation (ILAE
classiﬁcation, 1989) as Epilepsy with POS, epilepsy with continu-
ous spikes and waves during sleep (CSWS), absence epilepsy
(including childhood absence epilepsy and epilepsy with myo-
clonic absences), Infantile spasms, Dravet syndrome, Lennox–
Gastaut syndrome, myoclonic-astatic epilepsy, and other general-
ized epilepsies or unclassiﬁed.
The study comprised three phases: a 1 month baseline period
was followed by a 1 month titration period and a 5 month
evaluation period. Efﬁcacy and safety were assessed at 3 and 6
months. Later on, the child could be maintained on LVT for long-
term, at the discretion of the investigator. During the titration
period, LVT was added to the baseline therapy at the starting
dose of 10 mg/kg (20 mg/kg for infants under 2 years) daily for
two weeks, and then titrated to 20 mg/kg (40 mg/kg for under 2
years) daily for two weeks to the ﬁnal dose of 40 mg/kg (60 mg/
kg for under 2 years). The LVT dose was not increased in case of
complete seizure control and could be decreased in case of side
effects. The ﬁnal dose regimen that was reached was maintained
unchanged during the ﬁrst 3 months of the evaluation period and
could be adjusted for the following 3 months in case of
inadequate seizure control or side effects. The comedication
remained unchanged from baseline to the end of the 6 month
evaluation period.
2.2. Pharmacokinetics data
Among the 46 children included in a population pharmacoki-
netics study previously published,28 we selected the 21 for whom
LVT plasma trough concentrations were available at 3 months.
Blood samples were collected before the morning dose of LVT and
the assay for LVT was performed using high pression liquid
chromatography with UV detection.2.3. Data analysis
Analysis was performed on an intention to treat basis. Patients
with lost of follow-up, lack of efﬁcacy, adverse events and deviation
protocolwere consideredasnonresponders. Efﬁcacywasassessed in
the overall population at 3 and 6 month LVT based on seizure
frequencynormalized for 30 d (1) by comparing seizure frequency at
baseline with the frequency during the second and third month
evaluation period (primary endpoint) and during the last 3 month
evaluationperiod, (2)byevaluating thenumberof respondersduring
the same evaluation periods (i.e. more than 50% reduction of seizure
frequency on LVT compared to baseline), and (3) by evaluating the
number of seizure free children. The responder rate was also
evaluated at3 and6months according toepilepsy syndrome. Finally,
among the responders at 6 months, mean percentages of seizure
frequency decrease at 3 and 6 months (compared to baseline) were
compared using a paired Student’s t-test.
Univariate and multivariate analyses were conducted to
identify factors associated with the LVT response at 3 months
using logistic regression. The following factors were considered:
age (6 vs >6 years), sex, number of associated AEDs (1 vs 2 or 3)
and seizure frequency at baseline, number of AED failures in the
past 6 months, and duration, type (generalized vs partial) and
etiology (symptomatic, cryptogenic or idiopathic) of epilepsy.
Safety was assessed in the overall population based on the
adverse events reported by individuals and caretakers on
standardized side effect questionnaires.
Efﬁcacy/safety to LVT plasma concentration relationship was
also assessed at 3 months.
All categorical variables were expressed as percentage and
numbers, and continuous variableswere expressed asmedianwith
ﬁrst and third quartile (Q1–Q3). Unpaired median comparisons
were realized with the Mann–Whitney U test. Statistical analysis
was performed using Stata/SE 10.0 software (Stata Press, College
Station, TX, USA).
3. Results
LVT was administered to 102 children within the study over a 3
year period. Patients’ demographics are listed in Table 1. About half
the patients were aged between 6 and 12 years while 18% were
adolescents and 6% infants. Forty ﬁve percent had a brain lesion
and had epilepsy for more than 2 years. Two-third of them had
failed on at least one AED during the previous 6 months, mainly
clobazam (22%), topiramate (18%), vigabatrin (12%) or lamotrigine
(11%). Median seizure frequency was over one seizure a day. Most
patients received two concomitant AEDs, the most commonly
associated being valproate (52%), lamotrigine (33%), clobazam
(28%), vigabatrin (17%) and topiramate (13%). Epilepsy syndromes
are listed in Table 2: 41% of patients were diagnosed as partial
epilepsy, 35% as Epilepsy with POS (81% were symptomatic, 19%
were cryptogenic, none presented with idiopathic partial epilepsy)
and 6% as CSWS (presenting with generalized and partial seizures),
the following groups were generalized epilepsies, Infantile spasms
(16%), childhood absence epilepsy and Dravet syndrome around
10%, 6% of Myoclono-astatic epilepsy (Doose syndrome), and 13%
of other generalized epilepsy (mainly symptomatic generalized
epilepsies not classiﬁable into a known syndrome).
The ﬂow chart of the retention rate in the study is in Fig. 1.
3.1. Efﬁcacy
The responder rate was 36% (37/102) and 32% (33/102)
respectively at 3 and 6 month LVT, including 6 (5.8%) patients
seizure free at 3 months and 7 (6.8%) at 6 months. Six patients
(5.8%)were aggravated at 3 and 6monthswith over 50% increase in
Table 1
Baseline demographics and clinical characteristics (n=102).
Baseline characteristics
Sex, n (%)
Boys 58 (57)
Girls 44 (43)
Age, n (%)
6 months, 2 years 6 (6)
>2 years, 6 years 31 (30)
>6 years, 12 years 47 (46)
>12 years, 15 years 18 (17)
Previous duration of epilepsy, in years, median (IQR) 5 (2–7)
Epilepsy etiology, n (%)
Symptomatic 54 (53)
Cryptogenic 46 (45)
Idiopathic 2 (2)
Type of seizures, n (%)
Partial 37 (36)
Generalized 64 (63)
Undeﬁned 1 (1)
Number of AED failure and stopped during the previous 6 months before the
inclusion, n (%)
0 42 (41)
1 34 (33)
2 26 (26)
Number of seizure per month at baseline, median (IQR) 53 (12–167)
Number of associated AED at baseline, n (%)
One 21 (20)
Two 75 (74)
Three 6 (6)
Table 2
Epilepsy syndromes (n=102).
Epilepsy syndrome n (%) Median
age (years)
Age range
(years)
Epilepsy with partial onset
seizures
36 (35) 7 1–16
West syndrome 16 (16) 6 0.75–13
Childhood absence 12 (12) 9 3–15
Dravet syndrome 9 (9) 8 3–14
Myoclonic astatic epilepsy 6 (6) 5 4–9
Continuous spikes and waves
during sleep
6 (6) 10 6–13
Lennox–Gastaut syndrome 3 (3) 12.5 12–15
Other generalized epilepsy 14 (13) 6 1–16
S. Chhun et al. / Seizure 20 (2011) 320–325322seizure frequency compared to baseline. Among the 33 responders
at 6 months, seizure frequency decreased in mean by 66% (95%CI
[55–76]) at 3 month LVT and by 79% (95%CI [69–87]) at 6 months
compared to baseline (p paired Student’s t-test <0.01).
The median dose of LVT was 30.0 mg/kg/d at 3 months (n = 79,
Q1–Q3: 21.5–43.5 mg/kg/d) and 31.1 mg/kg/d at 6 months (n = 59,
Q1–Q3: 25.0–44.8 mg/kg/d), with 3 responders at doses under
10 mg/kg/d at 3 months and 2 at 6 months. Among children
receivingmore than 40 mg/kg/d (n = 29), 66%were non responders
and 17% presented with seizure aggravation.
[()TD$FIG]Visit 0 : Screening ; Assessed eligibility 
N=109
Visit 1 : Epileptic children receiving LVT 
N= 102
Visite 2 : Evaluation Visit at 1 month
N= 98
Visite 3 : Evaluation Visit at 3 months
N= 79
Visite 4 : Evaluation Visit at 6 months
N= 59
Epileptic children continuing LVT after the end of th
clinical study N= 35
Fig. 1. Flow chartAt 3 month LVT, patients with CSWS exhibited the highest
responder rate (67%, 4/6) with 3 patients being seizure free and no
patient aggravated (Fig. 2). For absence epilepsy, the responder
rate was 42% (5/12), and for Epilepsy with POS it was 39% (14/36),
respectively 14% and 45% in cryptogenics and symptomatics
(difference not signiﬁcant), with 2 seizure free patients. Responder
rate was 33% (2/6) for myoclonic-astatic epilepsy, including 1
seizure free, and 36% (5/14) for the other generalized epilepsies.
Within the small sample of patients with Lennox–Gastaut patients
syndrome, 1/3 responded. One to 2 patients were aggravated in all
of these syndromes except for Myoclono-astatic epilepsy, Dravet
syndrome and Lennox–Gastaut syndrome. The lowest responder
rate was for Infantile spasms (31%, 5/16) and Dravet syndrome
(11%, 1/9), for which no patient became seizure free whereas 2
with Infantile spasms were aggravated.
At 6 month LVT (Fig. 2), patients with CSWS still exhibited the
highest unchanged responder rate: the 4 responders (3 seizure free
and 1 with 92% seizure reduction) showed behavioral and
cognitive improvement, 2 had normal EEG and 2 remained with
CSWS. For absence epilepsy and Epilepsy with POS the responder
rate decreased compared to 3 month rate reaching respectively
33% (4/12) and 25% (9/36), keeping 1 seizure free patient and 36%e 
Non included N=7
Ineligible : 5
Withdrawn consent : 1 
Other : 1  
Discontinued N=4
Lack of efficacy : 2 
Lack of efficacy and adverse Event : 1
Protocol deviation : 1
Discontinued N=19
Lack of efficacy : 11
Adverse event : 3
Lost to follow up : 1
Protocol deviation : 1
Other : 3
Discontinued N=20
Lack of efficacy : 16
Lack of efficacy and adverse event : 1
Other : 3
of the trial.
[()TD$FIG]
Fig. 2. Response at 3 and 6 months on levetiracetam according to epilepsy
syndromes.
Table 3
(a) Factors associated with LVT response at 3 months and (b) LVT response at 3 and 6
Univariate analysis
n OR 95% CI
(a)
Sex
Boys 22/58 1
Girls 15/44 0.85 0.37–1.92
Age
6 years 9/37 1
>6 years 28/65 2.35 0.96–5.77
Type of epilepsy
Generalized 22/64 1
Partial 15/37 1.30 0.56–2.99
Etiology of epilepsy
Cryptogenic 15/46
Symptomatic 21/54 1.31 0.58–2.99
Duration of epilepsy
<6 years 19/58 1
6 years 18/44 1.46 0.65–3.28
Number of associated AED
1 7/21 1
2 or 3 30/81 1.17 0.43–3.24
At 3 months
n (%) OR 95% CI
(b)
Cryptogenic 1/7 (14.3) 1
Symptomatic 13/29 (44.8) 4.9 0.52–45.8
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not signiﬁcant). One patient escaped for myoclonic-astatic
epilepsy (the other one remained seizure free) and for the other
generalized epilepsies, whereas there was one more responder for
Infantile spasms). Efﬁcacy was maintained in the unique respon-
ders presenting with Dravet syndrome and Lennox–Gastaut
syndrome.
The univariate andmultivariate analyses did not show different
responder rates in seizures classiﬁed as partial (41%, 15/37,
OR = 1.3) or generalized (34%, 22/64, OR = 1) (Table 3). Neither the
previous duration of epilepsy nor the number of comedications,
two markers of the severity of epilepsy, were associated with the
response to LVT. Only the age tended to be a signiﬁcant predictor of
response with better efﬁcacy for children aged over 6 years
(OR = 2.40, p = 0.06).
3.2. Safety
Thirty-three adverse events were attributed to LVT at 3 months
and 39 at 6 months, 19 patients presenting with 2 or 3 adverse
events (Table 4). For 5.9% (6/102 patients) the events were
reported as severe and 4.9% (5/102) patients stopped LVT
prematurely for intolerability. The most frequently reported side
effects were hyperexcitability (17.5%), sleep disorders (12.6%) and
drowsiness (11.7%). Their frequency tended to be higher at 6 than 3
months on LVT, due to the attempt to increase the dose over 40 mg/
kg/d after 3 months in the non-responders. However, we did not
ﬁnd any signiﬁcant correlation between dose and behavior
tolerability.
3.3. Efﬁcacy/tolerability – plasma level relationship
The LVT plasma trough concentrations obtained at 3 months
involved 11 children with Epilepsy with POS, 4 with CSWS, 3 with
Infantile spasms, 1 absence, 1 Dravet syndrome and 1 other
generalized epilepsy. Themedian age of these 21 patients was 11.5
years (4.5–15.9 years). The median trough concentration was
7.2 mg/L (Q1–Q3 4.7–10.2 mg/L). Non responders (n = 8) showedmonths in ‘‘Epilepsy with partial onset seizures’’ subgroup according to etiology.
Multivariate analysis (n=102)
p OR 95% CI p
1
0.69 0.85 0.36–1.97 0.71
1
0.06 2.38 0.96–5.88 0.06
1
0.54 1.25 0.52–3.00 0.62
0.51 –
–
0.36 –
1
0.75 1.26 0.43–3.64 0.67
At 6 months
p n (%) OR 95% CI p
0/7 (0) 1
0.21 10/29 (35.5) 8.1 0.42–155 0.15
Table 4
Adverse events occurred during the clinical study (n=102).
All adverse
events at
3 months
Adverse
events
related to
LVT at 3
months
All adverse
events at
6 months
Adverse
events
related to
LVT at 6
months
At least one adverse event (AE)
Yes 44 33 48 39
Number of different types of AE
1 26 20 23 20
2 9 9 13 14
3 9 4 12 5
Type of AE
Loss of appetite 9 7 10 8
Weight loss 5 1 5 1
Abdominal pain 4 0 5 1
Nausea 1 0 2 1
Vomiting 5 3 6 3
Diarrhea 5 3 7 3
Drowsiness 11 10 14 12
Hyperexcitability 20 15 22 18
Sleep disorders 10 9 14 13
Hypotonia 1 1 2 1
Ataxia 5 5 5 5
Tremor 3 1 5 2
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ders (n = 13), respectively 10.1 mg/L (Q1–Q3 6.9–16.1 mg/L) and
5.4 mg/L (Q1–Q3 4.68–10.2 mg/L) (Mann–Whitney U test,
p = 0.03). Two non responder patients had the two highest
concentrations (>17 mg/L). No differencewas evidenced in plasma
concentrations between responders and non responders in
Epilepsy with POS (n = 11) and in CSWS (n = 4), but sample sizes
were small. Regarding safety, no signiﬁcant association was found
between adverse effects and plasma trough concentrations.
4. Discussion
Although LVT is currently extensively prescribed in childhood
epilepsy, the panel of refractory epilepsy syndromes has not been
entirely evaluated prospectively. In the present exploratory trial
according to syndromes, epileptic encephalopathy with CSWS
discloses the highest beneﬁt of LVT as adjunctive therapy. We also
conﬁrm the good response in Epilepsy with POS and suggest that
neither Doose nor Lennox–Gastaut patients are at risk of
aggravation, two conditions that share clinical features of CSWS
(drop attacks, cognitive deterioration and generalized spikewaves)
andwithwhich the diagnosis at onsetmay occasionally be difﬁcult
in childhood. The age over 6 years tends to be a predictive factor of
response sustaining a poor response in Infantile spasms and Dravet
syndrome. Tolerability is excellent up to a maximal dose of 40 mg/
kg/d. In spite of a limited sample, we assume that our results in
CSWS, together with those gathered from several convergent
retrospective reports, provide a valuable rational to design a
randomized-controlled trial with LVT dedicated to this syndrome.
The strategy of pediatric development for LVT has clearly
followed the classical pathways. However, a ﬁrst prospective trial
of this kind was recommended by the Commission of drugs of the
International League Against Epilepsy many years ago (ILAE
Commission, 1994), and has now become mandatory according
to the EMEA guidelines (www.ema.europa.eu, Aug 2010). Had this
been followed, the compound would have gathered arguments to
become the ﬁrst line drug as an alternative to valproic acid for
children13: it is well tolerated, has large range of efﬁcacy and does
not aggravate signiﬁcantly speciﬁc epilepsy syndromes. In addi-
tion, it comprises neither the disadvantage of altering the
metabolism of comedication or being altered by comedication,nor the risk of revealing an inborn error of metabolism, conditions
that, although they are rare, are often revealed by epileptic seizures
and challenging for both diagnosis antiepileptic drug treatment
strategy.
Among the open-labeled series of children treated with LVT for
pharmaco-resistant epilepsy only two are prospective and
consider epilepsy syndromes.9,15 Efﬁcacy data in our overall
population are comparable to those of both: respectively 36% and
32% vs 39% and 49% of responders, 6% and 7% vs 9% and 4.5% of
seizure free rate, and 7% vs 11% and 15% of patients aggravated.
Tolerability was quite good in our population, with hyperexcit-
ability and drowsiness as most frequent adverse events from
infancy to late childhood, as reported at any age, including the
placebo-controlled trials.1,2,7,9,15,17,18 Our median LVT dose also is
similar to that of the two other prospective trials, 34 vs 33 and
36 mg/kg/d. As far as children over 4 years are concerned, this dose
gave plasma concentrations in the same range as previously
reported in adults and children.20,29 However higher LVT doses did
not improve the patients in our series and even induced a seizure
worsening in some of them, so that wewould advice 40 mg/kg/d as
the maximum dose rather the 60 mg/kg/d targeted from age 4 in
partial onset seizures as previously recommended.30
We found a similar efﬁcacy rate in partial and generalized
epilepsy syndromes,which is consistentwith the large spectrumof
action extensively described with LVT and predictable from its
mechanism on the synaptic vesicle protein SV2A.31 However,
different epilepsy syndromes do not get the samebeneﬁt fromLVT:
CSWS and absence epilepsy get the highest, Infantile spasms and
Dravet the lowest. The efﬁcacy rate we observe in refractory
absences is comparable to that of a prospective Italian series.32 Age
over 6 years is a signiﬁcant factor for efﬁcacy in our study, and LVT
is indeed disappointing in Infantile spasms and Dravet syndrome.
Altogether, among the 23 patients with Infantile spasms prospec-
tively reported with LVT as adjunctive therapy (adding Lagae and
Grosso’s patients to our series), none became seizure free, a
requirement for this severe epileptic encephalopathy. Even in
newly diagnosed cases, few patients were controlled (2/5) on
LVT.33 LVT seems therefore deﬁnitely poor in Infantile spasms. On
the other hand, the encouraging results obtained in a prospective
Italian series of 28 Dravet patients16 contrast with the poor efﬁcacy
in our series. However, we presume that our Dravet patients were
more pharmacoresistant cases since they all had previously
received stiripentol compared to only 7% for the Striano series.
By contrast, LVT shows an efﬁcacy signal in CSWS with 2/3
responders and 50% becoming seizure free at 3 months of
treatment. Although our sample is small, these prospective results
are consistent with the favorable ﬁndings of several retrospective
reports: Capovilla et al. reported 3 patients in 2004,23 and soon
after there were 4 other series of respectively 12, 6, 17 and 4 CSWS
children, including symptomatic cases and idiopathic CSWS in the
context of BECTS without seizures.24–27 Overall, seizure frequency
decreased by over 50% in 21/35 (60%) patients whether CSWS was
symptomatic or idiopathic. EEG discharges also decreased by 75%
to 100% in a majority of patients, while behavior and cognition
improved.24,26 Our trial was not initially designed to focus on
CSWS so that prospective evaluations of sleep EEG and behavior/
cognition were not planned, although they should replace seizures
as primary endpoints in a syndrome-dedicated study. As in
Infantile spasms, seizures may be considered a target symptom in
CSWS: although their control is not sufﬁcient to cure the child,
their persistence certiﬁes that EEG is still abnormal and that the
cognitive risk persists.
Few AEDs may control CSWS, but none of them proved to be
efﬁcient in a randomized procedure, namely benzodiazepines,
ethosuximide, sulthiam34 and mainly high doses of steroids35 for
which there are life-threatening safety concerns. In addition, some
S. Chhun et al. / Seizure 20 (2011) 320–325 325of these drugs are poorly efﬁcient on the focal seizures that are
frequently associated with symptomatic CSWS. Alternatively the
AEDs of choice in focal seizures may aggravate CSWS, particularly
carbamazepine and oxcarbazepine, with occurrence of negative
myoclonus.36 In the context of BECTS, there is a risk of seizure and
EEG aggravation when using phenobarbital or carbamazepine, and
also lamotrigine to some extent.37,38 LVT has the advantage to be
efﬁcient on focal seizures, in both symptomatic and idiopathic
forms,15 and to prevent any worsening in CSWS and BECTS.
Finally, we did not ﬁnd any case of aggravation using LVT in
Myoclono-astatic epilepsy or in Lennox–Gastaut syndrome, two
syndromes which also present with drop attacks and whose
features are quite close to CSWS features, at least at onset (ILAE
classiﬁcation). With 33% responder patients in the former, our
ﬁndings are less favorable than suggested in one retrospective
series of 23 patients with Myoclono-astatic epilepsy.39 However,
our sample is small, and one patient became seizure free.
Based on these arguments and considering that half the 48
CSWS patients refractory to other drugs and entered into our
prospective and the retrospective studies improved, we assume
that LVT is deﬁnitely a good candidate for CSWS. However, despite
the need for new therapeutic agents, no randomized-controlled
trial has involved CSWS syndrome so far. The condition of orphan
therapeutics of this severe epilepsy is a big concern if we consider
that controlling epilepsy can minimize the cognitive sequelae. The
suggested efﬁcacy of LVT we presently highlight using a
prospective exploratory approach should be the main step before
a conﬁrmatory trial.
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